title: Antiviral effects of recombinant interferon alfa and clinical experience in viral infections.
abstract: Alpha interferons act virostatically by influencing several cellular enzymes involved in virus replication. The success of treatment with biosynthetic recombinant interferon alfa-2b (rIFN alfa-2b) has been confirmed in numerous clinical studies. Following intralesional injection, up to 56% of condylomata acuminata were totally eradicated. Laryngeal papillomatosis responded favourably to systemic therapy with various alpha-interferons, demonstrating complete remissions of up to 88%. Preliminary therapeutic trials using rIFN alfa-2b in chronic viral hepatitis (B, Delta, non-A, non-B) consistently showed beneficial effects on the disease-related biochemical, virological and histological parameters. Interferon alfa-2b proved particularly effective in the early stage of AIDS-associated Kaposi's sarcoma.
authors.affiliation: Essex Pharma GmbH, Munich, Fed. Rep. of Germany.
authors.forename: H T
authors.initials: HT
authors.lastname: Schneider
authors.forename: U
authors.initials: U
authors.lastname: Goldmann
mesh_terms: D000818:Animals; D000998:Antiviral Agents; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology* / Q000627:therapeutic use; D011994:Recombinant Proteins; D014777:Virus Diseases / Q000188:drug therapy*
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins